Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen McCormick

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 2